Evidence mostly coming from case reports or experiences in other solid tumors (especially melanoma and NSCLC) suggest that B-Raf-inhibitors, potentially in combination with MEK-inhibitors, might be a valuable therapeutic option for this rare cancer. Here, BRAF is linked to melanoma.